Related references
Note: Only part of the references are listed.Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber et al.
SCIENCE (2021)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Perspective: Designing T-Cell Engagers With Better Therapeutic Windows
Omid Vafa et al.
FRONTIERS IN ONCOLOGY (2020)
Radiopharmaceutical therapy in cancer: clinical advances and challenges
George Sgouros et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Isha Kapoor et al.
CELL DEATH & DISEASE (2020)
Development of therapeutic antibodies for the treatment of diseases
Ruei-Min Lu et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Richard W. Birkinshaw et al.
NATURE COMMUNICATIONS (2019)
An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
Steven Feins et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Human antibody-based chemically induced dimerizers for cell therapeutic applications
Zachary B. Hill et al.
NATURE CHEMICAL BIOLOGY (2018)
Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells
Jacob R. Petersburg et al.
ACS NANO (2018)
Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins
Alexander J. Martinko et al.
ELIFE (2018)
Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory
Sophie Viaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Fc-fusion Proteins in Therapy: An Updated View
Reza Jafari et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
William R. Strohl
BIODRUGS (2015)
A High Through-put Platform for Recombinant Antibodies to Folded Proteins
Michael Hornsby et al.
MOLECULAR & CELLULAR PROTEOMICS (2015)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Share Paper
